Your Kidney Biopsy and Pathology Report

A kidney biopsy is the key test for diagnosing the pattern of your kidney issues. It provides a detailed look at the damage occurring in your filtering units (glomeruli) ^[1]. However, finding the actual cause often still requires clinical lab work. To get the full picture, pathologists use three different microscopic techniques, each acting like a different lens on a camera. Your pathology report is essentially the summary of what they saw through these three lenses.

The Three Lenses of Pathology

To reach a final diagnosis of an MPGN pattern, the pathologist integrates findings from three distinct tests:

1. Light Microscopy (LM): This is the first level of magnification. It identifies the MPGN pattern, characterized by “tram-track” or double contours (where the filter walls look like they have two layers) and mesangial proliferation (too many cells in the filter’s support structure) ^[2][3].
2. Immunofluorescence (IF): This is the most critical step for modern classification. The pathologist uses glowing “tags” to see which proteins are stuck in your kidneys ^[1]. It identifies antibodies (immunoglobulins like IgG, IgA, or IgM) and “complement” proteins (like C3).
3. Electron Microscopy (EM): This uses a high-powered beam of electrons to see the tiniest details inside the filter walls. It can pinpoint exactly where deposits are located—under the lining, inside the wall, or in the support structure ^[4][5].

How IF Separates IC-MPGN from C3G

The modern classification of these diseases relies heavily on the Immunofluorescence (IF) results. The key is comparing the brightness of C3 (a complement protein) to the brightness of immunoglobulins (antibodies) ^[1][6]:

• Immune-Complex MPGN (IC-MPGN): Your biopsy will show significant amounts of both immunoglobulins and C3 ^[1]. This suggests your immune system is creating “clumps” that are getting stuck.
• C3 Glomerulopathy (C3G) Pattern: This is defined by C3 dominance. For a biopsy to meet this criteria, the C3 staining must be at least two “levels” (orders of magnitude) brighter than any other immune protein ^[6][7]. This suggests the “complement system” may be a primary driver. However, C3 dominance alone does not definitively prove primary C3G; some infections and monoclonal proteins can cause this pattern, making C3G a “clinicopathologic” diagnosis requiring additional clinical context.

Using EM to Distinguish C3GN from DDD

If your biopsy shows C3 dominance, the pathologist may then use Electron Microscopy (EM) to figure out which type of C3G you have:

• Dense Deposit Disease (DDD): The EM shows very dark, extremely dense, ribbon-like or “band-like” deposits tucked right inside the filter walls ^[8][9].
• C3 Glomerulonephritis (C3GN): The deposits are usually lighter in color, appear “smudgy” or granular, and can be found in various locations around the filter wall rather than just in the middle of it ^[10][9].

The “Unmasking” Technique: Pronase IF

Sometimes, standard IF can be misleading. In some patients—especially older adults—monoclonal proteins (related to blood disorders) can “hide” in the tissue and remain invisible during a standard frozen biopsy test ^[11].

If your doctor suspects there might be a hidden antibody issue, they may selectively order protease-digested paraffin immunofluorescence (often called pronase IF) ^[12]. This technique uses an enzyme to “digest” the tissue slightly, which can unmask hidden proteins. While not a routine requirement for every biopsy, it is a crucial tool when masked deposits are suspected.

Biopsy Completeness Checklist

A thorough pathology report for MPGN/C3G should include:

• Glomeruli Count: How many filters were sampled. Adequacy depends on tissue distribution rather than a strict 10-15 count rule, and the pathologist will note if the sample is sufficient.
• IF Intensity Scores: Specific 0–3+ brightness scores for C3, IgG, IgA, IgM, C1q, and light chains (Kappa and Lambda) ^[7].
• Chronic Damage Assessment: A description of any glomerulosclerosis (scarring) or interstitial fibrosis and tubular atrophy (IFTA), which helps predict long-term kidney health ^[13][14].
• EM Details: Clear descriptions of where the deposits are located and their density, when applicable ^[9].